newsfilter
← Latest News
GlobeNewswire·

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

On track to declare two in vivo editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025Company to present further in vivo HSC preclinical data and further in vivo preclinical data